MDL 72832 hydrochloride

Discontinued Product

MDL 72832 hydrochloride (Cat. No. 0412) has been withdrawn from sale for commercial reasons.
Cat.No. 0412 - MDL 72832 hydrochloride | C22H30N2O4.HCl | CAS No. 113777-40-5
Description: Potent 5-HT1A ligand
Chemical Name: 8-[4-(1,4-Benzodioxan-2-ylmethylamino)butyl]-8-azaspiro[4.5]decane-7,9-dione hydrochloride
Purity: ≥99% (HPLC)
Literature (5)

Biological Activity for MDL 72832 hydrochloride

MDL 72832 hydrochloride is a potent ligand at 5-HT1A receptors, with mixed agonist and antagonist properties. An agonist at post-synaptic 5-HT1A receptors.

Technical Data for MDL 72832 hydrochloride

M. Wt 422.95
Formula C22H30N2O4.HCl
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 113777-40-5
PubChem ID 45073438

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for MDL 72832 hydrochloride

References for MDL 72832 hydrochloride

References are publications that support the biological activity of the product.

Millan et al (1993) Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat - a pharmacological characterization of the actions of novel agonists and antagonists. J.Pharmacol.Exp.Ther. 264 1364 PMID: 8450471

Mir et al (1988) MDL 72832: a potent and stereoselective ligand at central and peripheral 5-HT1A receptors. Eur.J.Pharmacol. 149 107 PMID: 2840295

View Related Products by Target

View Related Products by Product Action

View all 5-HT1A Receptor Ligands

Keywords: MDL 72832 hydrochloride, MDL 72832 hydrochloride supplier, Potent, 5-HT1A, ligand, Serotonin, Receptors, 5-HT1, MDL72832, hydrochloride, 0412, Tocris Bioscience

Citations for MDL 72832 hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for MDL 72832 hydrochloride.

Reviews for MDL 72832 hydrochloride

There are currently no reviews for this product. Be the first to review MDL 72832 hydrochloride and earn rewards!

Have you used MDL 72832 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
5-HT Receptors

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.


Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.


Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.